The FDA has accepted fenebrutinib for priority review across two forms of multiple sclerosis following three Phase III studies, moving Roche toward a potential expansion of its MS portfolio beyond Ocrevus.
Key Investor Takeaways
- Genentech, part of Roche Group (USOTC:RHHBY), has received FDA priority review for fenebrutinib in both relapsing multiple sclerosis and primary progressive multiple sclerosis.
- Fenebrutinib reduced annualized relapse rates by 51.1% and 58.5% versus teriflunomide across the two Phase III FENhance studies.
- In the Phase III FENtrepid PPMS trial, fenebrutinib met the primary endpoint of non-inferiority to Roche’s Ocrevus for disability progression.
- Fenebrutinib produced a numerical 12% reduction in progression risk versus Ocrevus, but the reported 95% confidence interval of 0.75 to 1.03 included 1.0.
- FDA acceptance shifts attention from clinical development toward the regulatory decision, with approval potentially giving Roche an oral treatment spanning both RMS and PPMS.
Why RHHBY Stock Is in Focus
Genentech said the FDA has accepted its New Drug Application for fenebrutinib under priority review for both relapsing multiple sclerosis and primary progressive multiple sclerosis.
The application is supported by three Phase III trials covering both forms of the disease.
In FENhance 1, fenebrutinib reduced the annualized relapse rate by 51.1% compared with teriflunomide over 96 weeks, with a p-value below 0.001. FENhance 2 produced a 58.5% reduction, with a p-value below 0.00001.
Measures of disability progression also showed consistent trends favoring fenebrutinib over teriflunomide, according to Genentech.
In PPMS, the FENtrepid study met its primary endpoint by demonstrating non-inferiority to Ocrevus in reducing disability progression. Fenebrutinib produced a hazard ratio of 0.88 for 12-week composite confirmed disability progression, corresponding to a numerical 12% reduction in risk compared with Ocrevus.
Why This Matters for Investors
FDA priority review moves fenebrutinib closer to a potential commercial role alongside Roche’s existing MS franchise.
The breadth of the filing is particularly relevant. If approved for both indications, Genentech said fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment covering both RMS and PPMS.
That could give Roche an additional way to address the MS market while retaining Ocrevus, currently the only approved treatment for PPMS. Rather than simply targeting relapse control, fenebrutinib is designed to cross the blood-brain barrier and address both acute and chronic inflammation associated with disease progression.
The Phase III safety profile will also remain relevant during regulatory review. Serious adverse-event rates were 9% for both fenebrutinib and teriflunomide in FENhance 1, and 11% versus 6%, respectively, in FENhance 2. In FENtrepid, serious adverse events occurred in 19% of participants in both the fenebrutinib and Ocrevus groups.
Liver enzyme elevations occurred more frequently with fenebrutinib than Ocrevus in the PPMS study. Genentech also reported an imbalance in fatalities across the three pivotal trials, although it said the deaths occurred at different times and from various causes. Those findings are likely to remain an important component of the FDA’s benefit-risk assessment.
What to Watch Next
The FDA’s regulatory decision is now the central catalyst for fenebrutinib. Investors can watch for any additional regulatory updates, including potential labeling and safety requirements, as well as further analysis of the Phase III disability data.
If approved, attention would then shift toward how Roche positions oral fenebrutinib alongside Ocrevus and whether its combination of relapse reduction, disability data and oral administration supports adoption across the RMS and PPMS populations.